SCHEMBL17320175

SCHEMBL17320175

CNCCc1ccc(O)c(/N=N/c2ccc(C(C)=O)cc2)c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
MAPT P10636 6/20 0.49
MAPK1 P28482 3/20 0.49
HIF1A Q16665 2/20 0.49
HSD17B10 Q99714 2/20 0.49
TP53 P04637 1/20 0.49
CYP1A2 P05177 1/20 0.49
ALOX15 P16050 1/20 0.49
TSHR P16473 1/20 0.49
NFKB1 P19838 1/20 0.49
THPO P40225 1/20 0.49
KDM4E B2RXH2 3/20 0.48
SMN1; SMN2 Q16637 2/20 0.48
ALDH1A1 P00352 2/20 0.48
LMNA P02545 2/20 0.48
HPGD P15428 2/20 0.48
BLM P54132 2/20 0.48
GMNN O75496 1/20 0.48
GFER P55789 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17320889 0.88 MAPT (0.49) CA1CA2MAPTMAPK1HIF1A
SCHEMBL24346426 0.85 HTT (0.46) CA1CA2MAPTMAPK1HIF1A
SCHEMBL13820249 0.83 CA1 (0.58) CA1CA2MAPTMAPK1HSD17B10
SCHEMBL26324657 0.79 HPGD (0.49) CA1CA2MAPTTP53SMN1; SMN2
SCHEMBL15982271 0.76 KMT2A (0.63) MAPTMAPK1HIF1AHSD17B10TP53
SCHEMBL13523477 0.75 CA1 (0.46) CA1CA2TP53SMN1; SMN2ALDH1A1
SCHEMBL11147135 0.74 CA1 (0.72) CA1CA2MAPTMAPK1NFKB1
SCHEMBL11147132 0.74 CA1 (0.72) CA1CA2MAPTMAPK1NFKB1
SCHEMBL17773308 0.73 MAPT (0.58) CA2MAPTMAPK1HSD17B10KDM4E
SCHEMBL21787273 0.73 NME4 (0.40) CA1CA2MAPTHIF1AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10400024-B2 Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides SANQUIN REAGENTS B.V. (NL) 2019-09-03 US disclosed
US-20170101459-A1 CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES STICHTING SANQUIN BLOEDVOORZIENING (NL) 2017-04-13 US disclosed
WO-2015187019-A1 CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES STICHTING SANQUIN BLOEDVOORZIENING (NL) 2015-12-10 WO disclosed
EP-2952520-A1 Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides. Stichting Sanquin Bloedvoorziening (NL) 2015-12-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170101459-A1 CLEAVAGE AND EXCHANGE OF MAJOR HISTOCOMPATIBILITY COMPLEX LIGANDS EMPLOYING AZOBENZENE-CONTAINING PEPTIDES CD74, HLA-B, MICA CA1 942/4885CA2 3035/4885MAPT 4310/4885
US-10400024-B2 Cleavage and exchange of major histocompatibility complex ligands employing azobenzene-containing peptides CD74, HLA-B, MICA CA1 942/4885CA2 3035/4885MAPT 4310/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.